Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

El-Cheikh, Jean; Venton, Geoffroy; Crocchiolo, Roberto; Fürst, Sabine; Faucher, Catherine; Granata, Angela; Oudin, Claire; Coso, Diane; Bouabdallah, Réda; Vey, Norbert; Duran, Ségolène; Fougereau, Emmanuelle; Berger, Pierre; Chabannon, Christian; Blaise, Didier

doi:10.1038/bmt.2013.87

Cited by 17 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose of micafungin was chosen based on initial studies suggesting the need for higher doses of anti-mold prophylaxis compared to the dose needed for Candida. 20,21 It is possible that a lower dose of micafungin could be equally effective based on recent data showing effective anti-mold prophylaxis with a daily dose of 50-100 mg. 22,23 Mortality after IMI was high in our patients, consistent with prior reports, 8,24 especially for those with Mucorales, reflecting the aggressiveness of these infections even in the prophylactic era and indicating the need for continuing improvement in this field despite the low prevalence of IMI.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Sequential systematic anti‐mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation

Rosillo

Ávila

Huang

et al. 2018

Transplant Infectious Dis

View full text Add to dashboard Cite

Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk for invasive mold infections (IMI). The goal of the study is to describe the incidence and outcome of IMI in patients after allo-HSCT in a large cohort of patients receiving anti-mold prophylaxis. We conducted a retrospective review of 988 consecutive adults who underwent allo-HSCT in our center from 2008 through 2014. Standard prophylaxis consisted of micafungin 150 mg IV daily from admission to day +7 ± 3 followed by voriconazole until day +75 to +100. Cases meeting criteria for proven or probable IMI according to EORTC-MSG criteria were included. Median age at HSCT was 54 years. The most common diagnoses were acute myeloid leukemia (n = 351, 36%) and lymphoid malignancies (n = 248, 25%). Matched related or unrelated donors (URD) were used in 686 (69%) patients, mismatched URD in 142 (14%) and cord blood units in 154 (16%). Twenty-one patients were diagnosed with IMI after allo-HSCT, 19 probable and 2 proven, and one patient was diagnosed postmortem. Microbiological diagnosis was established in 9 cases, 5 of them being Aspergillus. One-year cumulative incidence (CI) of IMI was 1.6% (95% CI 0.9-2.5) while 12-week overall survival after IMI was 39% (95% CI 24-65) Analyzed by disease, there was a trend for a higher 1-year CI of IMI in patients with ALL (5% [95% CI 1.6-11.4]) when compared with AML (1.4%), MDS (1.5%) and lymphoma (1.2%), P = .06. The 1-year CI of IMI after transplantation is low in patients receiving anti-mold prophylaxis with micafungin bridged to voriconazole, although these infections are associated with a higher risk of mortality.

show abstract

Section: Discussionsupporting

confidence: 90%

“…The dose of micafungin was chosen based on initial studies suggesting the need for higher doses of anti‐mold prophylaxis compared to the dose needed for Candida . It is possible that a lower dose of micafungin could be equally effective based on recent data showing effective anti‐mold prophylaxis with a daily dose of 50‐100 mg …”

Section: Discussionmentioning

confidence: 99%

Sequential systematic anti‐mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation

Rosillo

Ávila

Huang

et al. 2018

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Investigators reported MCFG to be well tolerated. Both clinical effectiveness and well safety profile were in line with those in recent studies .…”

Section: Discussionsupporting

confidence: 89%

“…This study shows a favorable safety profile of MCFG as prophylaxis in high-risk patients with respect to adverse events: the reported rate of drug-related adverse and severe adverse events was low (approximately 1%) and comparable with other studies. In a study by El-Cheikh et al (28), no treatment-related adverse event was observed, while investigators of our study reported only 1 adverse event (skin rash in the 100-mg group) related to MCFG. Van Burik et al (11) reported a similar low rate of adverse or severe adverse events in patients treated with MCFG for prophylaxis of IFDs.…”

Section: Discussioncontrasting

confidence: 67%

See 1 more Smart Citation

Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato‐oncological high‐risk patients: a web‐based non‐interventional trial in four large university hospitals in Germany

Heimann

Vehreschild

Meintker

et al. 2014

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Girmenia

Barosi

Piciocchi

et al. 2014

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

This document updates and expands the recommendations on primary prophylaxis of invasive fungal diseases (IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, published in 2009 by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). A consensus process was undertaken to describe and evaluate current information and practice regarding risk stratification and primary antifungal prophylaxis during the pre-engraftment and postengraftment phases after allo-HSCT. The revised recommendations were based on the evaluation of recent literature including a large, prospective, multicenter epidemiological study of allo-HSCT recipients conducted among the GITMO transplantation centers during the period of 2008 to 2010. It is intended as a guide for the identification of types and phases of transplantation at low, standard, and high risk for IFD, according to the underlying disease, transplantation, and post-transplantation factors. The risk stratification was the critical determinant of the primary antifungal approach for allo-HSCT recipients.

show abstract

Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

Cited by 17 publications

References 26 publications

Sequential systematic anti‐mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation

Sequential systematic anti‐mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation

Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato‐oncological high‐risk patients: a web‐based non‐interventional trial in four large university hospitals in Germany

Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Contact Info

Product

Resources

About